Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration

European Journal of Pharmaceutical Sciences

Volumn 6, Issue 2, 1998, Pages 99-104

  Duquesnoy, C ^a   Mamet, J P ^a   Sumner, D ^b   Fuseau, E ^b  

^a Laboratoire Glaxo Wellcome   (France)

^b NONE

Author keywords

Absorption; Bioavailability; C(max) AUC(x),AUC(max); Deconvolution; Sumatriptan

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; DRUG ABSORPTION; DRUG FORMULATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; MIGRAINE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; STATISTICAL ANALYSIS;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION ROUTES; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; METABOLIC CLEARANCE RATE; MIDDLE AGED; SEROTONIN AGONISTS; SUMATRIPTAN; VASOCONSTRICTOR AGENTS;

EID: 0032055498     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(97)00073-0     Document Type: Article

References (14)

1. Becker W.J. A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalgia. 15(S14):1995;239t.
2. Chen M.L. An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm. Res. 9(11):1992;1380-1385.
3. Fowler P.A., Lacey L.F., Thomas M., Keene O.N., Tanner R.J., Baber N.S. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. 31(5):1991;291-294.
4. Göbel H. A placebo-controlled, dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Cephalgia. 15(S14):1995;232.
5. Humphrey P.P.A., Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends. Pharmacol. Sci. 12:1991;444-446.
6. Hussey E.K., Aubert B., Richard I., Kunka R.L., Fowler P. The clinical pharmacology of sumatriptan suppositories. Cephalgia. 15(S14):1995;233.
7. Lacey L.F., Keene O.N., Duquesnoy C., Bye A. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J. Pharm. Sci. 83(2):1994;212-215.
8. Lacey L.F., Keene O.N., Duquesnoy C., Bye A. Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies. Pharm. Res. 11(10):1994;S-415.
9. Lacey L.F., Hussey E.K., Fowler P.A. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur. J. Clin. Pharmacol. 47:1995;543-548.
10. Macheras P., Symillides M., Reppas C. The cut-off time point of the partial area method for assessment of rate of absorption in bioequivalence studies. Pharm. Res. 11(6):1994;831-834.
11. Moore, K.H.P., Hussey, E.K., Shaw, S., Fuseau, E., Duquesnoy, C., Pakes, G., 1996. Safety, tolerability and pharmacokinetics of sumatriptan in healthy volunteers following ascending single intranasal doses and multiple doses. Submitted to Cephalgia (June).
12. Pabst G., Jaeger H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur. J. Clin. Pharmacol. 38:1990;5-10.
13. Vaughan D.P., Dennis M. Mathematical basis of point-area deconvolution method for determining in vivo input functions. J. Pharm. Sci. 67:1978;663-665.
14. Volans G.N. Migraine and drug absorption. Clin. Pharmacokinet. 3:1978;313-318.